Funding Opportunities

Open Programs

• ASAP Collaborative Research Network

  

  Objective:

  The ASAP Collaborative Research Network, a program of the Aligning Science Across Parkinson’s (ASAP) initiative being implemented through The Michael J. Fox Foundation, seeks to support international, multidisciplinary, multi-institutional research teams to address key knowledge gaps in the basic disease mechanisms that contribute to Parkinson’s development and progression.

  Award Amount:

  Up to $9 million

  Due Date:

  Pre-proposals Due: January 8, 2020

  Learn more
• Ken Griffin Alpha-synuclein Imaging Competition

  

  Objective:

  The Michael J. Fox Foundation has prioritized alpha-synuclein imaging as the most likely imaging approach to have an impact for therapeutic development. The goal of this $10-million funding program is to deliver a selective alpha-synuclein PET tracer for use in clinical studies.

  Award Amount:

  Up to $8.5 million

  Due Date:

  January 17, 2020

  Learn more
• The Edmond J. Safra Fellowship in Movement Disorders

  Objective:

  Movement disorder specialists (neurologists with subspecialty training in Parkinson's disease and other movement disorders) serve as an important bridge between scientific advances in the lab and positive patient outcomes in the care setting.

  Award Amount:

  $90,000 per fellow per year

  Due Date:

  December 13, 2019

  Learn more

Programs in Review

• Therapeutic Pipeline Program

  Objective:

  The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.

  Award Amount:

  Up to $500,000 (pre-clinical) or $2 million (clinical)

  Learn more
• Use of Parkinson’s Disease Biosamples

  Objective:

  The Michael J. Fox Foundation seeks to facilitate access and use of our cohort biosamples. Applicants can request these human biosamples and associated grant funding for target validation or biomarker development programs.

  Award Amount:

  Up to $300,000

  Learn more
• CLIA Lab for Genetic Testing RFP

  Objective:

  We are seeking a CLIA laboratory to conduct genetic testing on samples from people who may carry a Parkinson's-related mutation.

  Award Amount:

  Reviewing Proposals

  Learn more
• Biology of Astrocytes in Parkinson’s Disease

  Objective:

  The Michael J. Fox Foundation will award one-year to 18-month grants for studies that explore the role of astrocytes in Parkinson’s disease (PD) pathology and the potential for astrocyte-focused therapeutics. The goals of this funding program are to further understanding of astrocyte biology in Parkinson’s and to rationalize the pursuit of astrocyte-specific targets and/or pathways for the treatment of the disease.

  Award Amount:

  Up to $150,000

  Learn more
• Assay Development and Validation for Quantifying Oligomeric Alpha-Synuclein

  Objective:

  The Michael J. Fox Foundation will award one-year grants for research to advance the development, optimization and validation of assays to quantify oligomeric alpha-synuclein in human body fluids. Prior research suggests that alpha-synuclein quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response and/or patient stratification.

  Award Amount:

  Up to $200,000

  Learn more
• Imaging Biomarkers to Track Disease Progression and Therapeutic Efficacy

  Objective:

  The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD.

  Award Amount:

  Up to $750,000

  Learn more
• Therapeutic Pipeline Program

  Objective:

  The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care. The Therapeutic Pipeline Program is an Edmond J. Safra Core Program for PD Research.

  Award Amount:

  Up to $500,000 (pre-clinical or applied tech) or up to $2 million (clinical)

  Learn more